AAIC 2024: Early Alzheimer’s disease patients reap sustained benefits from long-term lecanemab treatment
09 Dec 2024
byProf. Nick Fox, University College London, London, UK; Prof. Christopher van Dyck, Yale School of Medicine, Connecticut, US
At the Alzheimer’s Association International Conference (AAIC) 2024 held in Philadelphia, US, researchers presented latest findings on the use of the dual-acting, anti–amyloid beta (Aβ) protofibril antibody, lecanemab, for treatment of early Alzheimer’s disease (AD). Topics covered included the paradoxical brain volume changes associated with anti-amyloid immunotherapy and the 3-year clinical efficacy results of continuous lecanemab treatment from the phase III Clarity AD study.